| 王珏 张婷婷 李娟 隋丽丽 白莉.不同原发肿瘤位置对于西妥昔单抗联合化疗治疗K-ras 基因
野生型的转移性结直肠癌患者的预后比较[J].现代生物医学进展英文版,2016,16(6):1153-1155. |
| 不同原发肿瘤位置对于西妥昔单抗联合化疗治疗K-ras 基因
野生型的转移性结直肠癌患者的预后比较 |
| Comparison of the Prognosis of Different Primary Tumor Location in Patientswith K-ras Wild Type Metastatic Colorectal Cancer treated with CetuximabCombined Chemotherapy |
| |
| DOI： |
| 中文关键词: 原发肿瘤位置 转移性结直肠癌 预后 西妥昔单抗 |
| 英文关键词: mCRC Cetuximab Prognostic Primary tumor location |
| 基金项目: |
|
| Hits: 732 |
| Download times: 0 |
| 中文摘要: |
| 目的：探讨不同原发肿瘤位置对于西妥昔单抗治疗K-ras 基因野生型的转移性结直肠癌患者的预后影响。方法：回顾性分析
2008 年1月1 日至2013 年12 月31 日187 例我院行西妥昔单抗联合FOLFOX 或FOLFIRI 治疗的转移性结直肠癌患者，根据原
发肿瘤位置，以结肠左曲为分界点分为右半结肠癌和左半结肠癌两组，按照严格的配对标准进行1:2 配对，最终获得右半结肠癌
组16 例，左半结肠癌组32 例，进行分析，比较两组患者的近期疗效和无进展生存期。结果：右半结肠癌组ORR 为56.3％，左半结
肠癌组ORR 为62.5％，2 组比较差异无统计学意义（X2=0.174，P=0.676）。右半结肠癌组DCR 为87.5%，左半结肠癌组DCR 为
93.7%。2 组比较差异无统计学意义（X2=0.545，P=0.460）。右半结肠癌组的中位无进展生存时间（mPFS)为5.0 个月，左半结肠癌组
mPFS 为7.7 个月，两组差别有统计学意义（P＜0.05)。结论：K-Ras 基因野生型的左半结肠癌患者应用西妥昔单抗治疗，预后好于
右半结肠癌。 |
| 英文摘要: |
| Objective:To explore the influence of the prognosis of different primary tumor location in patients with K-ras wild
type metastatic colorectal cancer treated with cetuximab.Methods:The clinicopathologic data of 187 cases with K-ras wild type mCRC
who had treated with cetuximab combined with FOLFOX or FOLFIRI chemotherapy were analyzed retrospectively. Left-sided primary
tumors (LC)were defined as tumors from rectum to left flexure, while tumors in the remaining colon were regarded right-sided primary
tumors (RC). According to the strict standards for pairing 1:2 matched, 16 patients in RC and 32 patients in LC were statistically analyze.Results:The ORR in group RC and LC were 56.3%and 62.5%. The DCR in group RC and LC were 87.5% and 93.7%. There were no
significant differences in the objective response rate and disease control rate between two group. The median PFS in group RC and group
LC were 5 and 7.7 months, with a statistically significant difference(P＜0.05).Conclusion:Left sided primary tumors are associated with
favorable prognosis in patients with K-ras wild type mCRC treated with cetuximab. |
|
View Full Text
View/Add Comment Download reader |
| Close |
